PD L1 News and Research

RSS

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association annual meeting in May.

15 May 2022

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Immune checkpoint inhibitors are widely used to treat a variety of cancers; however, one serious side effect is the onset of type 1 diabetes.

6 May 2022

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Researchers assessed the efficacy and safety of using lithium for coronavirus disease 2019 (COVID-19) treatment.

5 May 2022

Study reveals a complexity to how the body "regulates the regulators" of the immune system

Checkpoint inhibitors have become important tools in the cancer-fighting arsenal. By blocking proteins that normally restrain the immune response, these drugs can help the immune system destroy cancer cells.

20 Apr 2022

Recent advances in non-viral nano-vector delivery of CRISPR/Cas9 genome editing payloads

Researchers reviewed non-viral nano-vectors used for delivering the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated genome editing system.

14 Apr 2022

New bioinformatics platform predicts optimal treatment combinations for cancer patients

Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations.

12 Apr 2022

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Combination immunotherapy reverses resistance to PD-1 inhibitors in patients with advanced melanoma

Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug – a CTLA-4 inhibitor such as the drug ipilimumab.

8 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

Natural compound found in cardamom shows promise for treating triple-negative breast cancer

Cardamonin -; a natural compound found in the spice cardamom and other plants -; could have therapeutic potential for triple-negative breast cancer, according to a new study using human cancer cells.

3 Apr 2022

Biological timeline of COVID-19 immune recovery described in new research

In a recent study published on the bioRxiv* preprint server, a group of researchers from the University of California, San Francisco, looked at intra-patient immunological changes over time to see if there were any changes in immune responses associated with successful COVID-19 resolution.

21 Mar 2022

Trial shows safety and immunogenicity of immunotherapy with chemoradiation in cervical cancer patients

A Phase I/Ib trial conducted by the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group NRG Oncology, NRG-GY017, concluded that the addition of the immunotherapy drug atezolizumab prior to and concurrently given with chemoradiation (CRT) treatment was safe for women with node-positive, locally advanced cervical cancer.

19 Mar 2022

Biomarkers to identify SARS-CoV-2 patients requiring invasive mechanical ventilation

Researchers evaluated biomarkers that could help identify COVID-19 patients needing invasive mechanical ventilation.

17 Mar 2022

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

Researchers determined the immune mechanisms associated with severe neurological manifestations of COVID-19.

7 Mar 2022

Study demonstrates that TMPRSS2, which is key to SARS-CoV-2 cell entry, is a tumor suppressor

The role played by the host enzyme TMPRSS2 in infection and cancer is the focus of a new study.

23 Feb 2022

Combined strategy suppresses the growth of deadly brain tumor

Short bursts of radiation therapy dramatically enhanced the efficiency of targeting glioblastomas with natural nanoparticle-based immunotherapy, thus suppressing growth of the deadly tumor, inducing anti-tumor immunity and prolonging survival in animal models, a research team at Massachusetts General Hospital has discovered.

31 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Fiber-rich diet may help some melanoma patients to respond to immunotherapy

A diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome, according to a new study led by researchers at the Center for Cancer Research at the National Cancer Institute, part of the National Institutes of Health, and the University of Texas MD Anderson Cancer Center.

23 Dec 2021

Nanoparticle therapeutic can be a potential new approach for treating malignant pleural effusion

Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).

16 Dec 2021